Cargando…

The Treat-to-Target Project in Atopic Dermatitis: One Year On

Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm i...

Descripción completa

Detalles Bibliográficos
Autores principales:	DE BRUIN-WELLER, Marjolein, DELEURAN, Mette, BIEDERMANN, Tilo, BISSONNETTE, Robert, FOLEY, Peter, GIROLOMONI, Giampiero, HERCOGOVÁ, Jana, HONG, Chih-Ho, KATOH, Norito, PINK, Andrew E., RICHARD, Marie-Aleth, SHUMACK, Stephen, SILVESTRE, Juan F., THYSSEN, Jacob P., WEIDINGER, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medical Journals Sweden, on behalf of the Society for Publication of Acta Dermato-Venereologica 2023
Materias:	Original Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134065/ https://www.ncbi.nlm.nih.gov/pubmed/37083095 http://dx.doi.org/10.2340/actadv.v103.5382

Ejemplares similares

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2021)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Flare management in atopic dermatitis: from definition to treatment
por: Girolomoni, Giampiero, et al.
Publicado: (2022)

Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey
por: AUGUSTIN, Matthias, et al.
Publicado: (2022)

Atopic Dermatitis: Identification and Management of Complicating Factors
por: Tamagawa-Mineoka, Risa, et al.
Publicado: (2020)

Targeting IL-4 for the Treatment of Atopic Dermatitis
por: Chiricozzi, Andrea, et al.
Publicado: (2020)

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs
por: Zuberbier, Torsten, et al.
Publicado: (2023)

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2022)

Overview of Atopic Dermatitis in Different Ethnic Groups
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

New Developments in Biomarkers for Atopic Dermatitis
por: Thijs, Judith L., et al.
Publicado: (2015)

Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort
por: Elsgaard, Stine, et al.
Publicado: (2021)

Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature
por: Heilskov, Sofine, et al.
Publicado: (2020)

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2020)

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
por: Griffiths, Christopher, et al.
Publicado: (2021)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
por: ACHTEN, Roselie, et al.
Publicado: (2023)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

Difficult to control atopic dermatitis
por: Darsow, Ulf, et al.
Publicado: (2013)

Exploratory analyses of biomarkers in blood and stratum corneum in patients with atopic dermatitis
por: Maruyama, Ayano, et al.
Publicado: (2022)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023)

Food allergen sensitization pattern in adults in relation to severity of atopic dermatitis
por: Röckmann, Heike, et al.
Publicado: (2014)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019)

Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation
por: Biedermann, Tilo, et al.
Publicado: (2015)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
por: Maurelli, Martina, et al.
Publicado: (2023)

Association Between Atopic Dermatitis and Educational Attainment in Denmark
por: Schmidt, Sigrun Alba Johannesdottir, et al.
Publicado: (2021)

Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry
por: LARSEN, Henrik H. P., et al.
Publicado: (2022)

The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis
por: ELSNER, Julie Sophie Hohwü, et al.
Publicado: (2020)

Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results
por: Nygaard, Uffe, et al.
Publicado: (2016)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Assessing patients’ characteristics and treatment patterns among children with atopic dermatitis
por: Geat, Davide, et al.
Publicado: (2021)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Netherton syndrome plus atopic dermatitis: Two new genetic mutations in the same patient
por: Moar, Agata, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7jibkeq3comob8q9n6ur0f9u0j